In brief: Pharmanet Group, Metabolic Pharmaceuticals, Genetic Technologies
Friday, 24 June, 2005
The sale of Pharmanet Group's (ASX:PNO) wholly owned subsidiary Medical Products Group, to Advance Healthcare (ASX:AHG), has been completed. A 90-day convertible note has been issued by Advance to Pharmanet, satisfying the $400,000 settlement payment.
David Kenley, VP corporate development and one of the founders of Metabolic Pharmaceuticals (ASX:MBP), has resigned from the company to become CEO of Xceed Biotechnology (ASX:XBL). Kenley will leave Metabolic on 1 July and join Xceed in mid July.
Henry Bosch has been appointed as a non-executive director of Genetic Technologies (ASX:GTG).
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
